Actosmet

Actosmet

pioglitazone + metformin

Manufacturer:

Celltrion Healthcare

Distributor:

DKSH
Concise Prescribing Info
Contents
Pioglitazone 15 mg, metformin HCl 850 mg
Indications/Uses
NIDDM patients already treated w/ a combination of pioglitazone & metformin, patients whose diabetes is not adequately controlled w/ metformin alone, or patients who initially responded to pioglitazone alone & require additional glycemic control.
Dosage/Direction for Use
Initially 1 tab once or bid based on the patient's current regimen of pioglitazone &/or metformin & gradually titrated after receiving adequate response. Max daily dose: Pioglitazone 45 mg & metformin 2,550 mg. To be given in divided doses.
Administration
Should be taken with food.
Contraindications
Type 1 diabetes, NYHA class III or IV heart failure, renal dysfunction, diabetic ketoacidosis. Patients w/ active bladder cancer.
Special Precautions
Evaluate serum ALT levels prior to initiation of therapy & periodically thereafter per clinical judgment of healthcare professional.
Adverse Reactions
Upper resp tract infection, headache, sinusitis, myalgia, tooth disorder, aggravated DM, pharyngitis, edema, anemia, decrease in Hb & hematocrit, wt gain, reversible elevation in ALT.
Drug Interactions
CYP2C8 inhibitors (eg, gemfibrozil), CYP2C8 inducers (eg, rifampicin), furosemide, nifedipine.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BD05 - metformin and pioglitazone ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Presentation/Packing
Form
Actosmet tab
Packing/Price
2 × 14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in